RHHBYNEUTRAL

RHHBY Revenue Growth (YoY) Analysis

-1.1%

Higher than 23% of Healthcare sector peers

Updated 1702h ago·SEC filings & market data

Key Takeaway

RHHBY (RHHBY) has a Revenue Growth (YoY) of -1.1% as of May 2026.

Sector Performance

23th percentile

RHHBY

-1.1%

Sector Median

6.2%

Sector Avg

4.2%

📊

Deep Analysis

RHHBY (RHHBY) has a Revenue Growth (YoY) of -1.1% as of May 2026.

This places RHHBY in the 23th percentile of the Healthcare sector, which has a median Revenue Growth (YoY) of 6.2% and a sector average of 4.2%. RHHBY's Revenue Growth (YoY) is 117.7% below the sector median, a significant divergence that warrants closer examination. In context: Year-over-year revenue acceleration is one of the strongest signals of business momentum. Sustained >15% growth is rare and typically re-rated by the market.

Frequently Asked Questions

What does the Revenue Growth (YoY) tell investors about RHHBY?

Year-over-year revenue acceleration is one of the strongest signals of business momentum. Sustained >15% growth is rare and typically re-rated by the market.

How is the Revenue Growth (YoY) calculated?

Revenue Growth (YoY) is calculated as: (Revenue_t - Revenue_t-4) / Revenue_t-4.

How does RHHBY's Revenue Growth (YoY) compare to its sector?

RHHBY's Revenue Growth (YoY) of -1.1% compares to a Healthcare sector median of 6.2%, placing it in the 23th percentile.

Who are RHHBY's closest peers by Revenue Growth (YoY)?

The closest Healthcare peers by Revenue Growth (YoY) include: ALGN (6.2%), AMGN (5.8%), ABT (7.8%), HIMS (3.8%), DGX (9.2%).

📚

Learn More About Revenue Growth (YoY)

How to Analyze Revenue Growth: More Than Just Rising Sales

Learn how to analyze revenue growth beyond the headline number. Master absolute vs percentage, YoY vs QoQ, and sustainable growth with real examples from NVDA, GOOGL, and MDB.

The Formula

(Revenue_t - Revenue_t-4) / Revenue_t-4

Why It Matters

Year-over-year revenue acceleration is one of the strongest signals of business momentum. Sustained >15% growth is rare and typically re-rated by the market.